Cargando…

Insulin resistance and cardiovascular disease

Insulin resistance (IR) and cardiovascular disease (CVD) represent two universal public health hazards, especially in today’s Western societies. A causal-effect relationship has been established that links IR with CVD. The mediating mechanisms are perplexing, under ongoing, rigorous investigation an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmas, Constantine E., Bousvarou, Maria D., Kostara, Christina E., Papakonstantinou, Evangelia J., Salamou, Evdokia, Guzman, Eliscer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069006/ https://www.ncbi.nlm.nih.gov/pubmed/36994866 http://dx.doi.org/10.1177/03000605231164548

Ejemplares similares

The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2022)

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
por: Kosmas, Constantine E., et al.
Publicado: (2023)

The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Primary genetic disorders affecting high density lipoprotein (HDL)
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics
por: Kostara, Christina E.
Publicado: (2023)

Effects of Diet, Lifestyle, Chrononutrition and Alternative Dietary Interventions on Postprandial Glycemia and Insulin Resistance
por: Papakonstantinou, Emilia, et al.
Publicado: (2022)

Editorial: Insulin resistance and cardiovascular disease
por: Stewart, Alan J., et al.
Publicado: (2023)

Association between insulin resistance and the development of cardiovascular disease
por: Ormazabal, Valeska, et al.
Publicado: (2018)

Cardiac Development and Transcription Factors: Insulin Signalling, Insulin Resistance, and Intrauterine Nutritional Programming of Cardiovascular Disease
por: Govindsamy, Annelene, et al.
Publicado: (2018)

Lipidomics in non-alcoholic fatty liver disease
por: Kartsoli, Sofia, et al.
Publicado: (2020)

Perivascular Fat and the Microcirculation: Relevance to Insulin Resistance, Diabetes, and Cardiovascular Disease
por: Houben, A. J., et al.
Publicado: (2011)

Roles of the Chemokine System in Development of Obesity, Insulin Resistance, and Cardiovascular Disease
por: Yao, Longbiao, et al.
Publicado: (2014)

Postprandial insulin resistance as an early predictor of cardiovascular risk
por: Lautt, W Wayne
Publicado: (2007)

Insulin and Insulin Resistance in Alzheimer’s Disease
por: Sędzikowska, Aleksandra, et al.
Publicado: (2021)

Aerobic vs anaerobic exercise training effects on the cardiovascular system
por: Patel, Harsh, et al.
Publicado: (2017)

Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences
por: Hong, So-hyeon, et al.
Publicado: (2020)

The Lymphatic System in Obesity, Insulin Resistance, and Cardiovascular Diseases
por: Jiang, Xinguo, et al.
Publicado: (2019)

Editorial: Insulin Resistance, Metabolic Syndrome, and Cardiovascular Disease
por: Yan, Tong, et al.
Publicado: (2022)

TGFβ Signaling and Cardiovascular Diseases
por: Pardali, Evangelia, et al.
Publicado: (2012)

Effect of Clinical and Laboratory Parameters on HDL Particle Composition
por: Kostara, Christina E., et al.
Publicado: (2023)

The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance
por: Abdelsalam, Shahenda S., et al.
Publicado: (2019)

The World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
por: Bloomgarden, Zachary T.
Publicado: (2023)

The world congress on insulin resistance, diabetes, and cardiovascular disease (WCIRDC)
por: Bloomgarden, Zachary
Publicado: (2022)

New Measure of Insulin Sensitivity Predicts Cardiovascular Disease Better than HOMA Estimated Insulin Resistance
por: Venkataraman, Kavita, et al.
Publicado: (2013)

CETP Inhibition: Past Failures and Future Hopes
por: Kosmas, Constantine E., et al.
Publicado: (2016)

Therapeutic Approaches and Role of ncRNAs in Cardiovascular Disorders and Insulin Resistance
por: Liyanage, Kalupahana Irushi Pamodya, et al.
Publicado: (2017)

The effectiveness of blood flow restriction training in cardiovascular disease patients: A scoping review
por: Angelopoulos, Pavlos, et al.
Publicado: (2023)

Sphingolipids: the nexus between Gaucher disease and insulin resistance
por: Fuller, Maria
Publicado: (2010)

Cardiovascular effects of basal insulins
por: Mannucci, Edoardo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1lmvu4dp6pdmi8d0u60e7pe3kd